EP2742154A4 - Biomarkerzusammensetzungen und verfahren damit - Google Patents

Biomarkerzusammensetzungen und verfahren damit

Info

Publication number
EP2742154A4
EP2742154A4 EP12821745.2A EP12821745A EP2742154A4 EP 2742154 A4 EP2742154 A4 EP 2742154A4 EP 12821745 A EP12821745 A EP 12821745A EP 2742154 A4 EP2742154 A4 EP 2742154A4
Authority
EP
European Patent Office
Prior art keywords
methods
biomarker compositions
biomarker
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12821745.2A
Other languages
English (en)
French (fr)
Other versions
EP2742154A2 (de
Inventor
Kirk Brown
Traci Pawlowski
David Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Switzerland Holdings GmbH
Original Assignee
Caris Life Sciences Switzerland Holdings GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Life Sciences Switzerland Holdings GmbH filed Critical Caris Life Sciences Switzerland Holdings GmbH
Publication of EP2742154A2 publication Critical patent/EP2742154A2/de
Publication of EP2742154A4 publication Critical patent/EP2742154A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
EP12821745.2A 2011-08-08 2012-08-08 Biomarkerzusammensetzungen und verfahren damit Withdrawn EP2742154A4 (de)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201161521333P 2011-08-08 2011-08-08
US201161523763P 2011-08-15 2011-08-15
US201161526623P 2011-08-23 2011-08-23
US201161529762P 2011-08-31 2011-08-31
US201161534352P 2011-09-13 2011-09-13
US201161537462P 2011-09-21 2011-09-21
US201161542639P 2011-10-03 2011-10-03
US201161551674P 2011-10-26 2011-10-26
US201161559676P 2011-11-14 2011-11-14
US201261612111P 2012-03-16 2012-03-16
US201261619803P 2012-04-03 2012-04-03
PCT/US2012/050030 WO2013022995A2 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods

Publications (2)

Publication Number Publication Date
EP2742154A2 EP2742154A2 (de) 2014-06-18
EP2742154A4 true EP2742154A4 (de) 2015-08-12

Family

ID=47669214

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12821745.2A Withdrawn EP2742154A4 (de) 2011-08-08 2012-08-08 Biomarkerzusammensetzungen und verfahren damit

Country Status (8)

Country Link
EP (1) EP2742154A4 (de)
JP (1) JP2014522993A (de)
KR (1) KR20140067001A (de)
CN (1) CN103874770A (de)
AU (1) AU2012294458A1 (de)
BR (1) BR112014002975A2 (de)
CA (1) CA2844671A1 (de)
WO (1) WO2013022995A2 (de)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103160509B (zh) * 2013-03-07 2015-02-18 新乡医学院第一附属医院 一种与食管癌术后早期复发和预后相关的miRNA标志物及其应用
CN105264092B (zh) * 2013-03-15 2019-02-22 得克萨斯州大学系统董事会 用于诊断和疗法的外来体中的miRNA生物发生
CN104076151B (zh) * 2013-03-29 2017-04-12 复旦大学附属华山医院 一种用于胶质瘤早期诊断的试剂盒
JP6556121B2 (ja) * 2013-04-29 2019-08-07 アポジェニックス アーゲー 癌を診断する方法
US10570455B2 (en) 2013-05-10 2020-02-25 University Of Southern California DNA methylation biomarkers for bladder cancer
AU2014305994B2 (en) * 2013-08-06 2019-02-21 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
AU2014312211A1 (en) 2013-08-28 2016-03-10 Caris Science, Inc. Oligonucleotide probes and uses thereof
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
US10139402B2 (en) 2013-11-06 2018-11-27 Jsr Corporation Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy of disease treatment drug, kit, and liquid composition
FR3014198B1 (fr) * 2013-12-03 2017-03-03 Biomerieux Sa Procede d'isolement d'exosomes
EP3078889B1 (de) * 2013-12-06 2019-09-18 The University of Tokyo Ventil, fluidsteuerungsstruktur, fluidvorrichtung und verfahren zur herstellung eines ventils
CN106796236A (zh) * 2013-12-30 2017-05-31 促进军事医学的亨利·M·杰克逊基金会公司 前列腺癌基因谱和使用所述基因谱的方法
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2019161126A1 (en) 2018-02-14 2019-08-22 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
CA2947512A1 (en) * 2014-05-01 2015-11-05 Stichting Vumc Small ncrnas as biomarkers
KR102401689B1 (ko) 2014-06-12 2022-05-25 도레이 카부시키가이샤 전립선암 검출 키트 또는 디바이스 및 검출 방법
ES2481819B1 (es) * 2014-06-12 2015-04-01 Sistemas Genómicos, S.L. Método de evaluación para evaluar una posibilidad de cáncer de mama
US20160038608A1 (en) * 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same
ES2792227T3 (es) * 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
KR101596166B1 (ko) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 유방암 진단 및 치료를 위한 마이크로 ｒｎａ의 용도
CN104313171A (zh) * 2014-11-06 2015-01-28 南京大学 一种诊断神经胶质瘤的microRNA分子标记物及其应用
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN105807063B (zh) * 2014-12-29 2018-02-06 中国人民解放军第二军医大学 Cd63在制备肝脏疾病诊断试剂盒或制备预防或治疗肝脏疾病药物中的应用
CN104548134A (zh) * 2015-01-04 2015-04-29 中国人民解放军第二军医大学 miR-144及其抑制剂的应用
WO2016112031A1 (en) * 2015-01-05 2016-07-14 The Johns Hopkins University Method of epigenetic analysis for determining clinical genetic risk
WO2016121821A1 (ja) * 2015-01-27 2016-08-04 Jsr株式会社 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016145128A1 (en) 2015-03-09 2016-09-15 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN104714032B (zh) * 2015-04-02 2015-09-16 闫星宇 用于产后子痫诊断的标志物及其检测试剂
US10709428B2 (en) 2015-05-01 2020-07-14 Dermtech, Inc. Non-invasive skin collection system
WO2016186215A1 (ja) * 2015-05-20 2016-11-24 Jsr株式会社 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CN104992058B (zh) * 2015-06-25 2017-08-01 成都厚立信息技术有限公司 疾病风险调整模型建立方法
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
CN105177117A (zh) * 2015-07-03 2015-12-23 张理义 重症抑郁障碍生物标记物、筛选方法及试剂盒
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
CN105039342B (zh) * 2015-08-06 2017-12-01 李家平 能抑制MAT2A基因表达的siRNA及其应用
US20180231565A1 (en) * 2015-08-09 2018-08-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
CN105067822B (zh) * 2015-08-12 2017-05-24 中山大学附属肿瘤医院 用于食管癌诊断的标志物
JP6583817B2 (ja) * 2015-09-04 2019-10-02 国立大学法人山口大学 子宮平滑筋における腫瘍の診断マーカー
JP6857185B2 (ja) * 2015-09-11 2021-04-14 アプタマー サイエンス インコーポレイテッドＡｐｔａｍｅｒ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3165926A1 (de) * 2015-11-06 2017-05-10 Humanitas Mirasole S.p.A. Verfahren zur charakterisierung von zellspezifischen mikrovesikeln
WO2017112921A1 (en) * 2015-12-24 2017-06-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
WO2017113565A1 (zh) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 基于蛋白标志物psg3辅助诊断肝癌或消化道癌症患者的试剂盒
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP4339288A3 (de) 2016-03-18 2024-06-05 Caris Science, Inc. Oligonukleotidsonden und verwendungen davon
CN105842461A (zh) * 2016-04-30 2016-08-10 广州恒泰生物科技有限公司 子宫肉瘤早中期快速诊断试剂盒及其制备方法
CA3025486A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN107475356A (zh) * 2016-06-08 2017-12-15 益善生物技术股份有限公司 骨肉瘤循环肿瘤细胞鉴定试剂盒
CN105907875A (zh) * 2016-06-13 2016-08-31 武汉泰安康生物科技有限公司 一种筛选肾癌外周血miRNA标志物的方法及肾癌标志物miR-378
JP6980219B2 (ja) * 2016-08-22 2021-12-15 いであ株式会社 がんを検出、又はがんの進行期を判定する方法
EP3541958A1 (de) * 2016-11-15 2019-09-25 Ventana Medical Systems, Inc. Zusammensetzungen und verfahren zur prognose behandlung und kolorektalkarzinom
CN108165635B (zh) * 2016-12-07 2021-07-13 南京农业大学 Kiaa1462基因启动子区变异位点及其在提高鹅产蛋性能上的应用
DE202017007364U1 (de) * 2016-12-16 2021-02-11 The Brigham And Women's Hospital Inc. Anordnung markierter Sensorelemente zum Erfassen unterschiedlicher Proteine, die unterschiedliche Sensorelemente binden
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
CN106636296A (zh) * 2016-12-22 2017-05-10 广州医科大学附属肿瘤医院 Hsp27在舌癌化疗耐受诊治中的应用
CN106501517B (zh) * 2016-12-27 2018-05-08 北京蛋白质组研究中心 检测血清中sparc蛋白的物质在制备筛查肝细胞癌试剂盒中的应用
CN106939340A (zh) * 2017-03-31 2017-07-11 哈尔滨医科大学 一种与肺腺癌转移及预后相关的分子标记物及其应用
CN106947820B (zh) * 2017-04-11 2020-09-29 成都望路医药技术有限公司 Vcan在结肠腺癌诊治中的用途
CN120636518A (zh) 2017-05-12 2025-09-12 密歇根大学董事会 个体和队列药理学表型预测平台
CN106987649A (zh) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 一种用于检测脑胶质瘤的引物组及检测方法
CN109085355A (zh) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 血清蛋白标志物组合在肺癌筛查和诊治中的应用
CN107273718A (zh) * 2017-06-27 2017-10-20 电子科技大学 一种融合dna甲基化特征的生存时间分析方法
JP7029719B2 (ja) * 2017-08-31 2022-03-04 静岡県 バイオマーカー
CN107630092B (zh) * 2017-10-23 2020-03-31 广州医科大学附属第二医院 miR-505-3p应用于前列腺癌骨转移的诊断、预后和治疗
US11971414B2 (en) * 2017-12-22 2024-04-30 Wisconsin Alumni Research Foundation Nanoengineered surfaces for cancer biomarker capture
CN107868829B (zh) * 2017-12-26 2021-05-18 浙江自贸区锐赛生物医药科技有限公司 评估脊索瘤术后复发风险的组合试剂、试剂盒及其应用
CN107937621A (zh) * 2018-01-12 2018-04-20 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） miRNA的应用、应用其的产品及检测方法
CN108192970A (zh) * 2018-01-24 2018-06-22 苏州大学 一种肝癌诊断标志物及其应用
CN108048460B (zh) * 2018-02-01 2021-04-09 浙江大学 一种新型分子标记及其在制备用于头颈癌诊断和预后的试剂盒中的应用
JP7455757B2 (ja) * 2018-04-13 2024-03-26 フリーノーム・ホールディングス・インコーポレイテッド 生体試料の多検体アッセイのための機械学習実装
FR3080185A1 (fr) * 2018-04-16 2019-10-18 Biomerieux Evaluation du risque de complication chez un patient suspecte d'avoir une infection ayant un score sofa inferieur a deux
CN108570501B (zh) * 2018-04-28 2020-06-12 北京师范大学 多发性骨髓瘤分子分型及应用
CN108559778B (zh) * 2018-04-28 2020-06-12 北京师范大学 多发性骨髓瘤分子分型及其在用药指导上的应用
CN108586579B (zh) * 2018-05-11 2021-11-30 京东方科技集团股份有限公司 一种类肽及其衍生物、盐、制备方法和用途
CN113855675A (zh) * 2018-05-22 2021-12-31 郑州大学第一附属医院 基于胆囊癌标志物的试剂盒及药物
CN108841962B (zh) * 2018-08-01 2021-11-19 博奥生物集团有限公司 一种非小细胞肺癌检测试剂盒及其应用
KR102094608B1 (ko) * 2018-08-08 2020-04-23 고려대학교 산학협력단 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법
US11535899B2 (en) 2018-08-10 2022-12-27 Toray Industries, Inc. Kit, device and method for detecting prostate cancer
CN109321656B (zh) * 2018-10-22 2021-10-01 上海交通大学医学院附属仁济医院 蛋白depdc1作为诊断三阴乳腺癌的标记物的用途
KR102731755B1 (ko) * 2018-11-01 2024-11-20 카오카부시키가이샤 피험체의 피부 세포에서 유래하는 핵산의 조제 방법
CN109507425A (zh) * 2018-11-07 2019-03-22 国家纳米科学中心 基于热泳细胞外囊泡的前列腺癌症复发监控系统及方法
KR20230155589A (ko) 2018-11-07 2023-11-10 시어 인코퍼레이티드 단백질 코로나 분석을 위한 조성물, 방법 및 시스템 및 그것들의 용도
WO2020104588A1 (en) * 2018-11-22 2020-05-28 Institut D'investigació Sanitària Pere Virgili Biomarkers of prostate cancer aggressiveness
CN109609630B (zh) * 2018-12-03 2023-01-13 哈尔滨医科大学 用于早期胃癌诊断的分子标志物及其应用
CN109439757A (zh) * 2018-12-18 2019-03-08 首都医科大学附属北京佑安医院 血浆外泌体miR-455-3p作为早期肝癌诊断标志物的应用
CN109652504B (zh) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 一种同时检测外泌体膜蛋白和mRNA的方法
EP3906031A4 (de) * 2019-01-02 2022-10-05 Zhejiang Crownmab Biotech Co. Ltd. Krebsbehandlung unter verwendung eines mehrfachzielgerichteten kinaseinhibitors in kombination mit proteinkinasebiomarkern
CN109609653B (zh) * 2019-02-12 2019-07-19 山东大学齐鲁医院 诊断或治疗胶质瘤的分子标记物及其应用
EP3699300A1 (de) * 2019-02-22 2020-08-26 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Samen-mirnas als nicht-invasive biomarker zur diagnose und/oder prognose von prostatakrebs
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
JP7518852B2 (ja) 2019-03-26 2024-07-18 シアー， インコーポレイテッド 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用
CN110196329A (zh) * 2019-05-31 2019-09-03 郑州大学第一附属医院 一种食管癌早期联合检测试剂盒
JP7562523B2 (ja) * 2019-06-27 2024-10-07 大塚製薬株式会社 エクソソームの測定方法およびエクソソームの測定キット
CN110279707A (zh) * 2019-07-05 2019-09-27 深圳市康宁医院(深圳市精神卫生研究所深圳市精神卫生中心) miR-212在制备用于治疗成瘾的药物中的应用
CN114502189A (zh) * 2019-07-19 2022-05-13 安特卫普大学 以屏障功能障碍为特征的疾病中的黏蛋白同种型
KR102346864B1 (ko) * 2019-07-24 2022-01-04 한국전자기술연구원 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법
CN117169534A (zh) 2019-08-05 2023-12-05 禧尔公司 用于样品制备、数据生成和蛋白质冠分析的系统和方法
CN110295228A (zh) * 2019-08-05 2019-10-01 中国人民解放军总医院第八医学中心 检测gata2的物质在制备诊断活动性结核病的试剂盒中的应用
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
CN110564867B (zh) * 2019-10-10 2022-06-24 扬州大学 一种秦川牛cfl1基因的snp分子标记及其检测方法
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
KR20220092902A (ko) * 2019-10-24 2022-07-04 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 진단
CN115244149B (zh) * 2019-12-27 2023-09-15 关西涂料株式会社 涂料的制作方法、预测色彩数据的方法以及计算机调色系统
WO2021173994A1 (en) * 2020-02-27 2021-09-02 The Trustees Of The University Of Pennsylvania Methods of using a multi-analyte approach for diagnosis and staging a disease
CN111647658B (zh) * 2020-06-05 2022-09-27 上海市第一人民医院 Linc00963相关致癌轴在前列腺癌远处转移的早期诊断和治疗中的应用
CN111690746A (zh) * 2020-06-30 2020-09-22 镇江维思生物科技有限责任公司 与肺癌相关的血小板rna标志物及其应用
CN113940999B (zh) * 2020-07-15 2022-11-29 中国农业大学 一种治疗非酒精性脂肪肝性肝病治疗靶点的应用
JP2023540904A (ja) 2020-08-25 2023-09-27 シアー， インコーポレイテッド タンパク質および核酸をアッセイするための組成物および方法
EP4212632A4 (de) * 2020-09-08 2024-07-17 Urotech. Co., Ltd. Verfahren zur berechnung des diagnostischen prostatakrebswerts und verwendungen davon
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用
CN112255408B (zh) * 2020-10-16 2023-04-14 牡丹江医学院 一种肿瘤生物标志物及肿瘤检测试剂盒
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112433053A (zh) * 2020-11-20 2021-03-02 四川大学华西医院 Tetraspanin-14蛋白检测试剂在制备肺癌筛查试剂盒中的用途
CN112301133B (zh) * 2020-12-01 2021-07-27 江门市中心医院 胆固醇生成基因标签在年轻乳腺癌患者预后预测中的应用
KR102427057B1 (ko) * 2020-12-04 2022-07-29 전남대학교산학협력단 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법
WO2022133621A1 (es) 2020-12-24 2022-06-30 Pontificia Universidad Católica De Chile Método in vitro para el diagnóstico y predicción de la agresividad de cáncer de tiroides, las posibilidades y tipo de cirugía de precisión para la remoción del tumor en un sujeto; kit; reactivos para conformar dicho kit; uso de los reactivos y uso de marcadores moleculares parte del método
CN113151460B (zh) * 2021-01-29 2022-10-18 复旦大学附属中山医院 一种识别肺腺癌肿瘤细胞的基因标志物及其应用
CN115166245A (zh) * 2021-04-04 2022-10-11 兰州大学第一医院 Clu及其组合物在诊断胆管癌中的应用及胆管癌诊断试剂盒
KR102540416B1 (ko) * 2021-04-09 2023-06-12 주식회사 애티스랩 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법
CN113125757B (zh) * 2021-04-22 2022-10-28 石河子大学 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法
US20220340962A1 (en) * 2021-04-22 2022-10-27 Genfit Quantitative detection of micro-rnas
CN113122544A (zh) * 2021-04-25 2021-07-16 杭州广科安德生物科技有限公司 一种特异性结合timp1蛋白的核酸适配体及其应用
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
JP2024521698A (ja) * 2021-05-21 2024-06-04 イェディテペ・ウニヴェルシテシ 子宮内膜症の診断における新規な生物学的マーカー
CN113186267A (zh) * 2021-06-07 2021-07-30 上海康黎诊断技术有限公司 一种人cyp2d6拷贝数变异和基因分型检测的引物探针组合、试剂盒以及方法
KR102510302B1 (ko) * 2021-06-11 2023-03-15 서울대학교산학협력단 알파-2-마크로글로불린을 유효성분으로 포함하는 요네병 진단용 바이오마커 조성물 내지 이의 용도
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
EP4373860A4 (de) * 2021-07-21 2025-05-21 Mercy Bioanalytics, Inc. Zusammensetzungen und verfahren zum nachweis von prostatakrebs
GB202111635D0 (en) * 2021-08-13 2021-09-29 Randox Laboratories Risk prediction model for prostate cancer
CN115792237A (zh) * 2021-09-09 2023-03-14 中国中医科学院中药研究所 一种早期预测心力衰竭的生物标志物
JPWO2023054436A1 (de) * 2021-09-29 2023-04-06
US20240417802A1 (en) * 2021-10-14 2024-12-19 The University Of Chicago Immunotherapeutic methods for treating cancer
CN113970641B (zh) * 2021-10-27 2025-02-11 南通大学附属医院 Cdc37在类风湿关节炎预防或治疗方面的应用
WO2023140658A1 (ko) * 2022-01-24 2023-07-27 고려대학교 산학협력단 뇌유래신경성장인자를 이용한 패혈증 진단, 예방 또는 치료용 약학적 조성물
JP2025510595A (ja) * 2022-03-10 2025-04-15 バザード・ファーマシューティカルズ・アクティエボラーグ がんの治療における使用のためのインターロイキン－１受容体１型の阻害剤
CN116735874B (zh) * 2022-03-11 2025-09-23 上海市免疫学研究所 结直肠癌肿瘤边界细胞亚群标志物组合及其应用
CN115166256B (zh) * 2022-06-16 2025-07-18 郑州大学第一附属医院 胶原蛋白中氨基酸位点修饰在胰腺癌检测中的应用
WO2024050856A1 (zh) * 2022-09-06 2024-03-14 南京市第一医院 一种辅助血细胞分析仪判定异常血小板聚集的方法和系统
KR20240058548A (ko) * 2022-10-26 2024-05-07 연세대학교 산학협력단 유방암 진단 또는 재발 예측을 위한 세포외 소포체 유래 miRNA 유전자 바이오마커 및 이의 용도
KR20240171887A (ko) * 2023-05-31 2024-12-09 이화여자대학교 산학협력단 미세먼지 노출 구분 및 미세먼지 노출에 의한 임신 관련 합병증 예측 방법
WO2025015065A2 (en) * 2023-07-10 2025-01-16 The Regents Of The University Of California Methods for determining prostate cancer
CN118675694B (zh) * 2024-07-23 2025-01-24 中国人民解放军海军第九七一医院 一种基于大数据的病患高压氧舱恢复效果分析系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2005042725A2 (en) * 2003-11-03 2005-05-12 Genenews, Inc. Liver cancer biomarkers
US20090203533A1 (en) * 2005-07-08 2009-08-13 Siemens Medicals Solutions Diagnositcs Gmbh Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100248225A1 (en) * 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
CA2705952C (en) * 2007-11-23 2018-05-01 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
EP2294196A1 (de) * 2008-06-06 2011-03-16 Centre National de la Recherche Scientifique - CNRS Verwendung des endolysosomalen systems und sezernierter vesikel (exosomenähnlich) bei behandlungen und diagnostik auf der basis kleiner rna sowie experimentelle untersuchung kleiner rna
EP2358912B1 (de) * 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Verfahren zur untersuchung von rna-mustern
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP2475989A4 (de) * 2009-09-09 2013-02-27 Gen Hospital Corp Verwendung von mikrovesikeln bei der analyse von kras-mutationen
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
CA2782284A1 (en) * 2009-11-30 2011-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems for isolating, storing, and analyzing vesicles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
T. DENG ET AL: "Abstract 444: Subpopulations of circulating microvesicles have different microRNA profiles", CANCER RESEARCH, vol. 71, no. 8 Supplement, 15 April 2011 (2011-04-15), pages 444 - 444, XP055168378, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2011-444 *
TA DENG ET AL: "Subpopulations of Circulating Microvesicles Have Different MicroRNA Profiles", 7 April 2011 (2011-04-07), XP055168385, Retrieved from the Internet <URL:http://www.carislifesciences.com/media/pdf/Spetzler-sorted-MiRs-AACR-poster-2011.pdf> [retrieved on 20150209] *
TRACI PAWLOWSKI ET AL: "Circulating exosomes may provide an alternate platform to monitor disease progression compared to circulating tumor cells CD-81 Labeled Exosome Level vs CTCs in Plasma Derived Exosomes miR-21 Copy Number vs CTCs in EpCAM+ Plasma Derived Exosomes", 5 July 2010 (2010-07-05), XP055168408, Retrieved from the Internet <URL:http://www.carislifesciences.com/media/pdf/ASCO_Pawlowski2010.pdf> [retrieved on 20150209] *

Also Published As

Publication number Publication date
KR20140067001A (ko) 2014-06-03
BR112014002975A2 (pt) 2017-03-01
JP2014522993A (ja) 2014-09-08
CN103874770A (zh) 2014-06-18
WO2013022995A3 (en) 2013-04-04
WO2013022995A2 (en) 2013-02-14
CA2844671A1 (en) 2013-02-14
EP2742154A2 (de) 2014-06-18
AU2012294458A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
EP2742154A4 (de) Biomarkerzusammensetzungen und verfahren damit
EP2721179A4 (de) Biomarkerzusammensetzungen und verfahren dafür
EP2922861A4 (de) Biomarkerzusammensetzungen und verfahren
EP2823306A4 (de) Biomarkerzusammensetzungen und verfahren
ES2953308T5 (en) Compositions and methods for analyte detection
EP2685807A4 (de) Screening-verfahren
EP2838954A4 (de) Haftzusammensetzungen und verfahren
DK2791160T3 (da) Modificerede mrna-sammensætninger
EP2885418A4 (de) Mikrokapselzusammensetzungen und verfahren dafür
EP2635254A4 (de) Zusammensetzungen und verfahren im zusammenhang mit verminderter schleimhautadhäsion
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
EP2791301A4 (de) Konzentrierte artikelwaschzusammensetzungen und verfahren dafür
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
PT2734049T (pt) Composições e métodos probióticos
EP2761294A4 (de) Biodosimetriepanelle und verfahren
BR112013023776A2 (pt) composição e abertura vedada com selante
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
BR112014010450A2 (pt) composição e método
EP2934585A4 (de) Anti-ntb-a-antikörper sowie verwandte zusammensetzungen und verfahren
PL3501499T3 (pl) Sposoby i kompozycje do wytwarzania aerozoli
EP2773358A4 (de) Zusammensetzungen und verfahren zur blutstillung
EP2750495A4 (de) Verfahren und zusammensetzungen zur aufrechterhaltung der festigkeit von wassermelonen
EP2823051A4 (de) Enzymatische nanosensorzusammensetzungen und verfahren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140226

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20150217BHEP

Ipc: G01N 33/68 20060101ALI20150217BHEP

Ipc: G01N 33/53 20060101ALI20150217BHEP

Ipc: G01N 33/566 20060101ALI20150217BHEP

Ipc: C12Q 1/68 20060101AFI20150217BHEP

Ipc: G01N 33/574 20060101ALI20150217BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BROWN, KIRK

Inventor name: SPETZLER, DAVID

Inventor name: PAWLOWSKI, TRACI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PAWLOWSKI, TRACI

Inventor name: BROWN, KIRK

Inventor name: SPETZLER, DAVID

A4 Supplementary search report drawn up and despatched

Effective date: 20150713

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20150707BHEP

Ipc: G01N 33/53 20060101ALI20150707BHEP

Ipc: G01N 33/574 20060101ALI20150707BHEP

Ipc: G01N 33/566 20060101ALI20150707BHEP

Ipc: C12Q 1/68 20060101AFI20150707BHEP

Ipc: G01N 33/68 20060101ALI20150707BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170927